Home > Protocol Summaries: Compounds > GW274150 Protocol Summaries: GW274150 GSKStudy ID Phase Title Status 104916 phase 2 An open-label, single dose study to investigate the safety, tolerability and pharmacokinetics of 90mg of GW274150 in adult and elderly RA subjects. Completed INO102141 Phase 1 A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthmatic response in subjects with mild asthma. Completed NOS102512 Phase 2 A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of doses of 5-180 mg of the iNOS inhibitor GW274150 in the Treatment of Acute Migraine during the Mild Headache Phase Completed NOS103325 Phase 2 A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 Weeks in the prophylactic treatment of migraine. Completed RA4102651 phase 1 An enabling study to investigate the correlation of biomarkers of the activity of inducible nitric oxide synthase (iNOS) with disease activity and treatment response in patients with rheumatoid arthritis(RA) Completed RA4104917 phase 2 A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects. Completed
